Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | HPGD | P15428 | 7/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137201 | 0.97 | MAPT (0.60) | MAPTALDH1A1HPGDLMNAGAA | |
| SCHEMBL5676827 | 0.79 | ALDH1A1 (0.65) | MAPTALDH1A1HPGDLMNAGAA | |
| SCHEMBL1637546 | 0.79 | ALDH1A1 (1.00) | MAPTALDH1A1HPGDLMNAGAA | |
| SCHEMBL5851585 | 0.77 | ALDH1A1 (0.97) | MAPTALDH1A1HPGDLMNAGAA | |
| SCHEMBL138163 | 0.77 | MAPT (0.62) | MAPTALDH1A1HPGDLMNAGAA | |
| SCHEMBL5676520 | 0.77 | ADORA1 (0.74) | MAPTALDH1A1HPGDLMNAGAA | |
| SCHEMBL136108 | 0.76 | MAPT (0.94) | MAPTALDH1A1HPGDLMNAGAA | |
| SCHEMBL31502680 | 0.75 | ALDH1A1 (0.67) | MAPTALDH1A1HPGDLMNAGAA | |
| SCHEMBL31502652 | 0.75 | ALDH1A1 (0.72) | MAPTALDH1A1HPGDLMNAGAA | |
| SCHEMBL5676825 | 0.74 | MAPT (0.61) | MAPTALDH1A1HPGDLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401441-A4 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | KING PHARMACEUTICALS RES & DEV (US) | 2006-09-06 | — | — | EP | claimed |
| US-20040077630-A1 | Allosteric adenosine receptor modulators | BARALDI PIER GIOVANNI (IT) | 2004-04-22 | — | — | US | claimed |
| EP-1401441-A2 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | King Pharmaceuticals Research and Development Inc. (US) | 2004-03-31 | — | — | EP | claimed |
| US-20020147185-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2002-10-10 | — | — | US | claimed |
| WO-2002074056-A2 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC. (US) | 2002-09-26 | — | — | WO | claimed |
| US-20010047008-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2001-11-29 | — | — | US | claimed |
| US-7112607-B2 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| EP-1401441-A4 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | KING PHARMACEUTICALS RES & DEV (US) | 2006-09-06 | — | — | EP | disclosed |
| US-6727258-B2 | E.G., KETONE DERIVATIVES OF THIENOTHIOPYRANS, BENZOTHIOPHENES, THIENOPYRIDINES, CYCLOPENTATHIOPHENES, THIOPHENYLNAPHTHALENES, THIOPHENYLBENZOFURANS, ETC. | KING PHARMACEUTICAL RESEARCH & DEVELOPMENT, INC. | 2004-04-27 | — | — | US | disclosed |
| US-20040077630-A1 | Allosteric adenosine receptor modulators | BARALDI PIER GIOVANNI (IT) | 2004-04-22 | — | — | US | disclosed |
| EP-1401441-A2 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | King Pharmaceuticals Research and Development Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20020147231-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. | 2002-10-10 | — | — | US | disclosed |
| US-20020147185-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2002-10-10 | — | — | US | disclosed |
| US-20020143004-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. | 2002-10-03 | — | — | US | disclosed |
| WO-2002074056-A2 | ALLOSTERIC ADENOSINE RECEPTOR MODULATORS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| US-20010047008-A1 | Allosteric adenosine receptor modulators | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2001-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147231-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | MAPT 4840/4885ALDH1A1 424/4885HPGD 1124/4885 |
| US-20040077630-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | MAPT 4793/4885ALDH1A1 291/4885HPGD 972/4885 |
| US-20010047008-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | MAPT 4793/4885ALDH1A1 291/4885HPGD 972/4885 |
| US-20020143004-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | MAPT 4839/4885ALDH1A1 328/4885HPGD 1035/4885 |
| US-20020147185-A1 | Allosteric adenosine receptor modulators | ADORA2A, ADORA1, ADORA2B | MAPT 4839/4885ALDH1A1 328/4885HPGD 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.